• Mylan launches DURART R 450 expressbpd
    November 17, 2017
    Mylan has serious concerns about Teva’s ability to integrate and efficiently run a combined company, and deliver meaningful shareholder value, he said, adding “there is simply no track record for investors to find”. (Reuters)
PharmaSources Customer Service